A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors
This research is looking into a new drug, MK-1200, for individuals who have advanced solid tumours. The study is split into two main parts. First, it will carefully check how safe MK-1200 is and what side effects it might cause. This is very important for any new treatment. Next, it will examine how well the drug works, such as if it can shrink tumours or stop them from growing. Researchers will also look at how the body handles the drug. This is an open-label study, meaning both you and your doctor will know if you are receiving MK-1200. This study hopes to find out if MK-1200 could be a helpful future treatment option.
At a glance
What is this study about?
This study is investigating a new medication called MK-1200 for people who have advanced solid tumours. "Advanced" means the cancer has grown or spread, and "solid tumours" refers to cancers that form a lump, like breast, lung, or bowel cancer. This research combined two early stages of testing (Phase 1 and Phase 2) into one project. The main goal of the first part is to understand how safe MK-1200 is and to find the right dose. This involves closely watching for any side effects and how your body reacts to the medicine.
The second part of the study focuses on how effective MK-1200 is in treating these advanced solid tumours. Researchers will look at whether the drug can make tumours smaller or stop them from growing. They will also study how the drug moves through your body, how much of it stays in your system, and how long it continues to work. All this information helps doctors understand if MK-1200 could be a valuable new treatment option for cancer in the future.
Finding new ways to treat advanced solid tumours is very important, as existing treatments don't work for everyone. This study aims to gather crucial information about MK-1200 to see if it could offer hope to patients. This isn't a guaranteed cure, but it's a vital step in discovering new and better ways to fight cancer.
Key takeaways
- This study tests a new drug, MK-1200, for advanced solid tumours.
- It aims to find out if the drug is safe and effective.
- Participants will receive MK-1200 and have regular medical checks.
- Both you and your doctor will know you are receiving MK-1200.
- The study is for adults aged 18 and over with advanced solid tumours.
Who may be eligible?
To join this study, people generally need to be 18 years old or older. There isn't an upper age limit mentioned, so older adults could also be considered.
Crucially, participants must have a type of advanced solid tumour. This means cancers that form a lump, such as lung cancer, breast cancer, or colon cancer, which have either grown or spread to other parts of the body.
Beyond age and cancer type, there will be other important health checks to make sure the treatment is safe for you. These often include blood tests, checks of your heart and kidney function, and usually require you to be well enough to take part in the study and attend appointments.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of an advanced solid tumour?
- Are you able to travel for regular hospital or clinic visits?
- Are you generally well enough to take part in a study?
What does participation involve?
If you join this study, you'll receive the MK-1200 medication. You will have regular visits to the hospital or clinic, where the study team will carry out various checks. These check-ups will likely include blood tests, physical examinations, and scans (like CT or MRI scans) to monitor your health and see how the medication is affecting your tumour.
The study team will carefully monitor you for any side effects you might experience. They will also track how the drug works in your body. The exact duration of your participation will depend on how you respond to the treatment and your overall health, but you will be monitored throughout. You'll need to commit to attending these regular appointments and following the study instructions closely.
Potential risks and benefits
Locations (4)
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedPoland
Common questions
What is a 'solid tumour'?
A solid tumour is a mass of cells that forms a lump, unlike blood cancers like leukaemia. Examples include breast, lung, and prostate cancer.
What does 'advanced' mean in this study?
In this context, 'advanced' means the cancer has grown or spread from where it started to other parts of the body.
What is MK-1200?
MK-1200 is a new experimental drug for treating advanced solid tumours. This study is trying to understand if it's safe and if it works.
Will I know if I am getting the real drug?
Yes, in this 'open-label' study, you and your doctors will know that you are receiving the MK-1200 medication.
What are 'Phase 1' and 'Phase 2' studies?
Phase 1 studies primarily check for safety and find the right dose of a new drug. Phase 2 studies then look to see if the drug works and continue to monitor for safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.